BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Emulate - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Emulate
X-ORIGINAL-URL:https://emulatebio.com
X-WR-CALDESC:Events for Emulate
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
TZID:Europe/Berlin
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260929T110000
DTEND;TZID=America/New_York:20260929T120000
DTSTAMP:20260925T011441
CREATED:20260914T182119Z
LAST-MODIFIED:20260914T182119Z
UID:11559-1790679600-1790683200@emulatebio.com
SUMMARY:Advancing the Human Liver-Chip Toward FDA Qualification: A New Era for DILI Prediction
DESCRIPTION:Drug-induced liver injury (DILI) remains one of the most difficult safety challenges in drug development. Despite extensive preclinical testing\, some drug candidates that appear safe in conventional models can still cause serious liver injury in patients\, contributing to clinical-stage failures\, regulatory setbacks\, and post-market withdrawals. The major reason is simple: traditional preclinical models do not always reproduce the complex\, human-specific biology that determines how the liver responds to a drug. \nEmulate’s Human Liver-Chip was developed to help close that translational gap. In a landmark study evaluating 27 small molecule drugs with known clinical outcomes\, the Liver-Chip identified DILI liabilities with 87% sensitivity and 100% specificity\, including drugs associated with severe liver injury that had not been reliably predicted by animal testing. \nThat body of evidence has now reached an important regulatory milestone: Emulate recently submitted its Full Qualification Package to the FDA’s ISTAND program\, advancing the Human Liver-Chip into the final stage of qualification as a Drug Development Tool for DILI assessment. \nIn this webinar\, Daniel Levner\, Ph.D.\, Chief Technology Officer at Emulate and lead author of the ISTAND application\, will explain the scientific foundation behind the Liver-Chip\, how it can complement existing approaches to liver safety assessment\, and what FDA qualification could mean for drug developers seeking more human-relevant evidence earlier in development. \nThe webinar will also feature updated data from Emulate’s AVA™ Emulation System\, demonstrating how Liver-Chip performance translates from the established Zoë® platform to an automated\, higher-throughput format capable of supporting larger studies. As the Human Liver-Chip advances toward qualified Drug Development Tool status\, researchers have an opportunity to incorporate the technology into their programs today\, generating decision-grade\, human-relevant data that can strengthen drug development decisions now and position teams for an evolving regulatory landscape. \nKey Learning Points \n\nHow the Human Liver-Chip models key aspects of liver physiology\, including multicellular interactions\, perfusion\, and clinically relevant drug exposure.\nWhat the Liver-Chip’s predictive performance means for drug developers\, including results demonstrating 87% sensitivity and 100% specificity across drugs with known clinical outcomes.\nHow Liver-Chip data can strengthen safety decision-making\, helping researchers identify liabilities earlier and generate additional human-relevant evidence alongside existing nonclinical approaches.\nHow the science translates from Zoë to AVA\, with updated data demonstrating consistent Liver-Chip performance in an automated\, higher-throughput platform.\nWhy now is the time to begin building Organ-Chip capabilities\, as the Human Liver-Chip advances through the final stage of FDA qualification and the regulatory role of human-relevant methods continues to expand.
URL:https://emulatebio.com/event/advancing-the-human-liver-chip-toward-fda-qualification-a-new-era-for-dili-prediction/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://emulatebio.com/wp-content/uploads/2026/09/Website-Webinar-Thumbnail-ISTAND-Sept-2026.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261001T110000
DTEND;TZID=America/New_York:20261001T120000
DTSTAMP:20260925T011441
CREATED:20260828T174439Z
LAST-MODIFIED:20260828T174439Z
UID:11516-1790852400-1790856000@emulatebio.com
SUMMARY:Development of a Human Endometrium-on-a-Chip to Model Human Embryo Adhesion
DESCRIPTION:Embryo implantation is a crucial step for the establishment of pregnancy and consists of three sequential stages: apposition\, adhesion to the endometrium\, and invasion into the decidua. Among these\, embryo adhesion is a highly coordinated process that remains poorly understood due to the lack of physiologically relevant human in vitro models capable of capturing these early events. To address this challenge\, researchers from the Carlos Simon Foundation have developed a human Endometrium-on-a-Chip using Emulate’s Organ-on-a-Chip technology to recreate the dynamic endometrial microenvironment. \nThe Endometrium-on-a-Chip was established by combining organoid-derived endometrial epithelial cells in the upper channel with primary endometrial stromal cells in the lower channel. The model was optimized to generate a stable and hormonally responsive endometrial tissue and characterized through the assessment of epithelial polarization\, extracellular vesicle secretion\, epithelial receptivity\, and stromal decidualization. \nSingle-cell RNA sequencing was performed to define the cellular composition of the model and characterize the identity and heterogeneity of both epithelial and stromal populations. The platform was further used to investigate how pharmacological disruption of endometrial receptivity with mifepristone influences embryo attachment\, with changes in receptivity-associated gene expression confirming the effect of the treatment. \nThe model was validated by introducing mouse embryos as a proof of concept\, demonstrating its suitability for studying the initial stages of embryo implantation. Human blastocysts were then incorporated into the platform to capture and characterize the events associated with embryo adhesion\, revealing trophectoderm-mediated attachment\, embryo reorganization\, and trophoblast functionality and differentiation. \nTogether\, these findings establish the Endometrium-on-a-Chip as a robust and physiologically relevant platform for investigating early embryo implantation and endometrial receptivity. The versatility of the model also provides a foundation for future applications\, including modeling endometrial disorders and evaluating pharmacological modulation in a human-relevant in vitro system. \nThis webinar will be hosted by Select Science. Please use the link above to register.
URL:https://emulatebio.com/event/development-of-a-human-endometrium-on-a-chip-to-model-human-embryo-adhesion/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://emulatebio.com/wp-content/uploads/2026/08/Website-Webinar-Thumbnail-Select-Science-Endometrium-Oct-2026.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261013
DTEND;VALUE=DATE:20261016
DTSTAMP:20260925T011441
CREATED:20260724T184655Z
LAST-MODIFIED:20260731T194653Z
UID:11402-1791849600-1792108799@emulatebio.com
SUMMARY:Festival of Biologics EU 2026
DESCRIPTION:Meet Emulate at Festival of Biologics 2026 — Booth #156 \nJoin Emulate at Festival of Biologics 2026\, taking place October 13-15 in Basel\, Switzerland. This leading conference brings together scientists\, innovators\, and biopharma teams focused on advancing antibody therapeutics\, immunotherapies\, and next-generation biologics. \nVisit Booth #156 to see live demonstrations of the AVA™ Emulation System and the Zoë-CM2® Culture Module\, two Organ-on-a-Chip platforms that bring human-relevant biology and automation to biologics R&D. With the US FDA identifying biologics — particularly monoclonal antibodies — as the first drug class they intend to move away from animal testing for by 2030\, the need for predictive\, human-specific models has never been greater. \nTogether\, AVA and Zoë offer practical solutions for teams seeking to reduce reliance on animal models\, increase predictive confidence\, and align with accelerating regulatory expectations for NAMs in biologics development. \nStop by Booth #156 to see the technology in action and learn how Emulate’s Organ-on-a-Chip technology can accelerate safer\, more effective biologics discovery.
URL:https://emulatebio.com/event/festival-of-biologics-eu-2026/
CATEGORIES:In Person
ATTACH;FMTTYPE=image/png:https://emulatebio.com/wp-content/uploads/2026/07/Festival-of-Biologics-Basel-2026-v2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261027T110000
DTEND;TZID=America/New_York:20261027T120000
DTSTAMP:20260925T011441
CREATED:20260915T195529Z
LAST-MODIFIED:20260921T170355Z
UID:11564-1793098800-1793102400@emulatebio.com
SUMMARY:From Organoids to Organ-on-a-Chip: New Opportunities for Livestock Research
DESCRIPTION:While Organ-on-a-Chip technology is increasingly being used to improve our understanding of human biology and advance drug development\, it also offers new opportunities to better understand animal physiology\, nutrition\, and health. \nIn this webinar\, Dr. Nicole Reisinger of dsm-firmenich will share the development and application of porcine Intestine-Chip and Liver-Chip models designed to investigate responses to deoxynivalenol (DON)\, a common mycotoxin in animal feed that can negatively affect livestock health and performance. \nTo investigate how DON affects different aspects of porcine physiology\, the dsm-firmenich team applied Organ-on-a-Chip technology across both intestinal and liver models. Using Emulate’s Zoë® Culture Module\, they established a porcine Intestine-Chip to evaluate effects on epithelial barrier function\, inflammatory signaling\, and cellular metabolism\, as well as a porcine Liver-Chip to study hepatotoxicity and metabolic responses. \nThe team then transferred the Liver-Chip model to Emulate’s AVA Emulation System™\, expanding the work onto a platform designed to support greater experimental scale and more integrated workflows. By applying the same Organ-Chip model across the complementary Zoë and AVA platforms\, the work demonstrates how researchers can build on established biology while scaling studies to support broader applications in animal nutrition\, health\, and toxicology. \nDr. Reisinger will also discuss ongoing efforts to expand these approaches into bovine models\, highlighting the broader potential for Organ-on-a-Chip technology across livestock species and research applications. \nKey Learning Points \n\nDiscover how porcine Intestine-Chip and Liver-Chip models can recreate tissue-specific aspects of livestock biology under physiologically relevant conditions.\nLearn how these models were used to investigate intestinal and hepatic responses to the mycotoxin deoxynivalenol (DON).\nSee how the porcine Liver-Chip model is being implemented on the AVA Emulation System™ to support integrated\, scalable Organ-Chip experimentation.\nExplore how Organ-Chip approaches could expand the toolkit available for animal nutrition\, health\, and toxicology research across multiple livestock species.
URL:https://emulatebio.com/event/from-organoids-to-organ-on-a-chip-new-opportunities-for-livestock-research/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://emulatebio.com/wp-content/uploads/2026/09/Website-Webinar-Thumbnail-DSM-Austria-Oct-2026.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261112T110000
DTEND;TZID=America/New_York:20261112T120000
DTSTAMP:20260925T011441
CREATED:20260921T200041Z
LAST-MODIFIED:20260921T200041Z
UID:11575-1794481200-1794484800@emulatebio.com
SUMMARY:Modeling natural HIV infection\, immunopathogenesis\, and antiretroviral therapy in a Lymphoid Organ-Chip
DESCRIPTION:Secondary lymphoid organs play a central role in HIV infection\, serving as important sites of viral replication\, immune dysfunction\, and viral persistence. Yet\, studying these complex interactions in a physiologically relevant human system remains challenging. Conventional in vitro models often require artificial immune cell activation and can struggle to capture key features of the human immune response to HIV. \nIn this webinar\, Dr. Hongshuo Song from University of South Florida will share how she used Emulate Organ-on-a-Chip technology to create a Lymphoid Organ-Chip to model HIV infection in a dynamic\, human-relevant microenvironment. The model supports high-density human immune cells within a 3D extracellular matrix\, enabling researchers to investigate how HIV interacts with immune cells in conditions designed to more closely resemble human lymphoid tissue. \nDr. Song demonstrated that multiple HIV strains could productively replicate in the Lymphoid Organ-Chip without artificial T cell activation. The model also recapitulated several hallmarks of HIV immunopathogenesis\, including CD4 T cell depletion\, changes in the CD8/CD4 ratio\, and immune activation. When treated with antiretroviral therapy\, viral replication was rapidly suppressed\, further demonstrating the model’s potential for studying therapeutic response. \nTogether\, these findings highlight the potential of the Lymphoid Organ-Chip as a human-relevant platform for investigating HIV infection\, immunopathogenesis\, and viral persistence. The model may also provide new opportunities to study emerging therapies and strategies aimed at achieving long-term viral remission or a functional cure. \nKey Learning Points \n\nHow a human Lymphoid Organ-Chip can model HIV infection without the artificial T cell activation commonly required in conventional in vitro systems\nHow the model reproduces key features of HIV immunopathogenesis\, including CD4 T cell depletion and immune activation\nHow antiretroviral therapy affects HIV replication within the Lymphoid Organ-Chip\nHow this human-relevant model could support research into HIV persistence\, therapeutic response\, and future functional cure strategies
URL:https://emulatebio.com/event/modeling-natural-hiv-infection-in-a-lymphoid-organ-chip/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://emulatebio.com/wp-content/uploads/2026/09/Website-Webinar-Thumbnail-USF-HIV-Nov-2026.png
END:VEVENT
END:VCALENDAR